Recognition of heterogeneous lymphokine-activated killer (LAK) receptors on Kaposi's sarcoma cells, endothelial cells, and monocytes/macrophages: evidence of distinct LAK-cell antigen on Kaposi's sarcoma cells--potential for use of LAK cells for immunotherapy.
The purpose of this study was to determine the potential use of lymphokine-activated killer (LAK) cells against Kaposi's sarcoma (KS) cells. We used chromium release cold-target inhibition assay for understanding the expression of heterogeneous LAK-cell antigens (Ags) on KS cells, endothelial cells (ECs), and monocytes/macrophages (M phi) which could allow for the utilization of LAK-cell immunotherapy in KS without side effects. Our data show that (i) all three cell types express the CD18 Ag of LFA-1 or Leu-CAM, (ii) rare KS cells from eyes cannot cold target-inhibit ECs, (iii) KS cells express a distinct LAK-cell Ag, which we have called LAK-KS Ag, and (iv) LAK-KS Ag allows for cold-target inhibition between different KS cells. The identification of LAK-KS Ag and a monoclonal antibody capable of inhibiting lysis of ECs and M phi without obstructing LAK-KS Ag would be important.
Rahman
M U
MU
Norris Cancer Hospital and Research Institute, Los Angeles, California 90033.
Mazumder
A
A
D015703:Antigens, CD / Q000032:analysis; D018821:CD18 Antigens; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D004727:Endothelium / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000276:immunology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008264:Macrophages / Q000276:immunology*; D009000:Monocytes / Q000276:immunology*; D011971:Receptors, Immunologic / Q000032:analysis; D012514:Sarcoma, Kaposi / Q000276:immunology* / Q000628:therapy*
D015703:Antigens, CD; D018821:CD18 Antigens; D007376:Interleukin-2; D011971:Receptors, Immunologic